MX2022014199A - Usos y formulaciones de los cannabinoides. - Google Patents

Usos y formulaciones de los cannabinoides.

Info

Publication number
MX2022014199A
MX2022014199A MX2022014199A MX2022014199A MX2022014199A MX 2022014199 A MX2022014199 A MX 2022014199A MX 2022014199 A MX2022014199 A MX 2022014199A MX 2022014199 A MX2022014199 A MX 2022014199A MX 2022014199 A MX2022014199 A MX 2022014199A
Authority
MX
Mexico
Prior art keywords
cannabinoids
formulations
cannabidiol
covid
patients suffering
Prior art date
Application number
MX2022014199A
Other languages
English (en)
Inventor
Mirko Nowak
Jesko Jay Nowak
Reinhard Nowak
Norbert Pöllinger
Original Assignee
Add Advanced Drug Delivery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Add Advanced Drug Delivery Tech Ltd filed Critical Add Advanced Drug Delivery Tech Ltd
Publication of MX2022014199A publication Critical patent/MX2022014199A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Se proporcionan los usos y formulaciones de los cannabinoides, en particular del cannabidiol. Los cannabinoides, en particular el cannabidiol, son usados para el tratamiento de pacientes que sufren de COVID-19, una enfermedad causada por el coronavirus SARS-Cov-2. Las formulaciones son especialmente para administración oral de los cannabinoides, en particular del cannabidiol. Estas formulaciones son útiles para el tratamiento de pacientes que sufren de COVID-19.
MX2022014199A 2020-05-11 2020-05-11 Usos y formulaciones de los cannabinoides. MX2022014199A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2020/063086 WO2021228365A1 (en) 2020-05-11 2020-05-11 Uses and formulations of cannabinoids

Publications (1)

Publication Number Publication Date
MX2022014199A true MX2022014199A (es) 2022-12-06

Family

ID=70861443

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014199A MX2022014199A (es) 2020-05-11 2020-05-11 Usos y formulaciones de los cannabinoides.

Country Status (11)

Country Link
US (1) US20230181484A1 (es)
EP (1) EP4149445A1 (es)
JP (1) JP2023534361A (es)
CN (1) CN115884759A (es)
AR (1) AR122059A1 (es)
AU (1) AU2020447636A1 (es)
BR (1) BR112022021640A2 (es)
CA (1) CA3181940A1 (es)
IL (1) IL298060A (es)
MX (1) MX2022014199A (es)
WO (1) WO2021228365A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023225554A1 (en) * 2022-05-17 2023-11-23 The Regents Of The University Of California Cannabinoids and il-15 activate nk cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008024490A2 (en) 2006-08-24 2008-02-28 Theraquest Biosciences, Inc. Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use
CN105848646B (zh) 2013-10-29 2019-10-22 艾克制药有限公司 包含大麻二酚的压制片剂、其制造方法以及此类片剂在口服治疗精神病症或焦虑症中的用途
GB2542797A (en) * 2015-09-29 2017-04-05 Gw Pharma Ltd Use of cannabinoids in the treatment of inflammatory skin diseases
WO2018035030A1 (en) 2016-08-15 2018-02-22 Corr-Jensen Inc. Time release fat-soluble actives
WO2019155337A1 (en) * 2018-02-06 2019-08-15 Scicann Therapeutics Inc. Compositions comprising a cannabinoid and punicalagin and methods of use thereof

Also Published As

Publication number Publication date
BR112022021640A2 (pt) 2022-12-13
US20230181484A1 (en) 2023-06-15
JP2023534361A (ja) 2023-08-09
EP4149445A1 (en) 2023-03-22
CA3181940A1 (en) 2021-11-18
IL298060A (en) 2023-01-01
CN115884759A (zh) 2023-03-31
AR122059A1 (es) 2022-08-10
WO2021228365A1 (en) 2021-11-18
AU2020447636A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
ATE420632T1 (de) Titrationsdosierschema für kontrolliert freigesetztes tramadol
ECSP045029A (es) Composiciones de valdecoxib de disgregación intraoral
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
MX2023006561A (es) Formulaciones farmaceuticas transdermicas que comprenden cbd o thc para el tratamiento del cancer.
AR119158A1 (es) Tratamientos de angioedema hereditario
MX2022014034A (es) Métodos para tratar covid-19 con el uso de bardoxolona metilo o análogos de esta.
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
AR119159A1 (es) Tratamientos de angioedema
WO2021062231A3 (en) Cannabinoid prodrug compounds
MX2022014199A (es) Usos y formulaciones de los cannabinoides.
MX2023006551A (es) Tratamiento de las convulsiones refractarias.
BRPI0513186A (pt) composição medicinal para a administração oral
BR112012009362A2 (pt) fração bioativa de petiveria alliacea, composição farmacêutica contendo a mesma e combinação com agentes imunoestimulantes para o tratamento de câncer
MX2022014198A (es) Usos y formulaciones de los cannabinoides.
MA31227B1 (fr) Composition pharmaceutique renfermant du phloroglucinol et du paracetamol.
CA3199014A1 (en) Combination therapy for the treatment of a liver disease
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2021004138A (es) Metodos y formulaciones para tratar nauseas y vomito inducidos por quimioterapias.
MX2022011651A (es) Composicion farmaceutica para tratamiento de diabetes.
HUP0301408A2 (hu) Szulodexid alkalmazása diabetikus vesebetegség kezelésére szolgáló orális gyógyszerkészítmény előállítására
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
MX2021015338A (es) Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma.
BR112022003126A2 (pt) Conjugado terapêutico
NO20042586L (no) Behandlingsfremgangsmate